Database references:

Citations

• Akinyinka, OO, et al. 2000. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. European Journal of Clinical Pharmacology. 56(2).
• Benowitz, NL, et al. 1995. Sympathomimetic effects of paraxanthine and caffeine in humans. Clinical Pharmacology and Therapeutics. 58(6).
• Campbell, ME, et al. 1987. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 15(2).
• Dorrbecker, SH, et al. 1988. Caffeine disposition in the pregnant rabbit. II. Fetal distribution of caffeine and paraxanthine during chronic maternal caffeine administration. Developmental Pharmacology and Therapeutics. 11(2).
• Dulloo, AG, et al. 1994. Paraxanthine (metabolite of caffeine) mimics caffeine's interaction with sympathetic control of thermogenesis. The American Journal of Physiology. 267(5 Pt 1).
• Fuhr, U, et al. 1994. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics. 4(3).
• Geraets, L, et al. 2006. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations. Biochemical Pharmacology. 72(7).
• Guerreiro, S, et al. 2008. Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Molecular Pharmacology. 74(4).
• Gómez-Ruiz, JA, et al. 2007. In vitro antioxidant activity of coffee compounds and their metabolites. Journal of Agricultural and Food Chemistry. 55(17).
• Hawke, TJ, et al. 1999. K+ transport in resting rat hind-limb skeletal muscle in response to paraxanthine, a caffeine metabolite. Canadian Journal of Physiology and Pharmacology. 77(11).
• Hawke, TJ, et al. 2000. Paraxanthine, a caffeine metabolite, dose dependently increases [Ca(2+)](i) in skeletal muscle. Journal of Applied Physiology (Bethesda, Md. : 1985). 89(6).
• Klebanoff, MA, et al. 1999. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. The New England Journal of Medicine. 341(22).
• Koch, JP, et al. 1999. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. Biomedical Chromatography : BMC. 13(4).
• Kull, B, et al. 1999. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochemical Pharmacology. 57(1).
• Labedzki, A, et al. 2002. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. Biochemical Pharmacology. 63(12).
• Laughon, SK, et al. 2011. Caffeine and insulin resistance in pregnancy. American Journal of Perinatology. 28(7).
• Okuro, M, et al. 2010. Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. Sleep. 33(7).
• Perera, V, et al. 2010. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomedical Chromatography : BMC. 24(10).
• Roux, A, et al. 2012. Annotation of the human adult urinary metabolome and metabolite identification using ultra high performance liquid chromatography coupled to a linear quadrupole ion trap-Orbitrap mass spectrometer. Analytical Chemistry. 84(15).
• Roy, AC, et al. 2009. Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids. Bioorganic & Medicinal Chemistry Letters. 20(1).
• Weinstein, D, et al. 1975. The effect of methylxanthines on chromosomes of human lyphocytes in culture. Mutation Research. 31(1).
• York, RG, et al. 1986. Teratogenicity of paraxanthine (1,7-dimethylxanthine) in C57BL/6J mice. Teratology. 34(3).